DR. DATSONS LABS | AUROBINDO PHARMA | DR. DATSONS LABS/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | 18.0 | - | View Chart |
P/BV | x | 0.2 | 3.9 | 4.2% | View Chart |
Dividend Yield | % | 0.0 | 0.3 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
AUROBINDO PHARMA Mar-19 |
DR. DATSONS LABS/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 830 | 15.1% | |
Low | Rs | 31 | 527 | 5.9% | |
Sales per share (Unadj.) | Rs | 133.0 | 333.9 | 39.8% | |
Earnings per share (Unadj.) | Rs | 0.2 | 40.4 | 0.4% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 51.8 | 12.8% | |
Dividends per share (Unadj.) | Rs | 0 | 2.50 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 128.8 | 237.1 | 54.3% | |
Shares outstanding (eoy) | m | 31.66 | 585.91 | 5.4% | |
Bonus/Rights/Conversions | FCCB | ESOP | - | ||
Price / Sales ratio | x | 0.6 | 2.0 | 29.0% | |
Avg P/E ratio | x | 516.1 | 16.8 | 3,069.6% | |
P/CF ratio (eoy) | x | 11.8 | 13.1 | 90.3% | |
Price / Book Value ratio | x | 0.6 | 2.9 | 21.2% | |
Dividend payout | % | 0 | 6.2 | 0.0% | |
Avg Mkt Cap | Rs m | 2,477 | 397,569 | 0.6% | |
No. of employees | `000 | NA | 17.9 | 0.0% | |
Total wages/salary | Rs m | 56 | 25,849 | 0.2% | |
Avg. sales/employee | Rs Th | NM | 10,956.9 | - | |
Avg. wages/employee | Rs Th | NM | 1,447.7 | - | |
Avg. net profit/employee | Rs Th | NM | 1,324.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 195,636 | 2.2% | |
Other income | Rs m | 79 | 1,553 | 5.1% | |
Total revenues | Rs m | 4,289 | 197,189 | 2.2% | |
Gross profit | Rs m | 569 | 39,519 | 1.4% | |
Depreciation | Rs m | 204 | 6,680 | 3.1% | |
Interest | Rs m | 430 | 2,626 | 16.4% | |
Profit before tax | Rs m | 13 | 31,767 | 0.0% | |
Minority Interest | Rs m | 0 | 27 | 0.0% | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
Tax | Rs m | 6 | 7,269 | 0.1% | |
Profit after tax | Rs m | 5 | 23,645 | 0.0% | |
Gross profit margin | % | 13.5 | 20.2 | 66.9% | |
Effective tax rate | % | 48.0 | 22.9 | 209.9% | |
Net profit margin | % | 0.1 | 12.1 | 0.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 153,645 | 4.5% | |
Current liabilities | Rs m | 6,711 | 120,429 | 5.6% | |
Net working cap to sales | % | 3.3 | 17.0 | 19.7% | |
Current ratio | x | 1.0 | 1.3 | 80.0% | |
Inventory Days | Days | 161 | 135 | 119.0% | |
Debtors Days | Days | 318 | 64 | 500.0% | |
Net fixed assets | Rs m | 3,673 | 103,909 | 3.5% | |
Share capital | Rs m | 317 | 586 | 54.0% | |
"Free" reserves | Rs m | 3,761 | 138,322 | 2.7% | |
Net worth | Rs m | 4,078 | 138,908 | 2.9% | |
Long term debt | Rs m | 1,671 | 1,800 | 92.8% | |
Total assets | Rs m | 12,633 | 264,544 | 4.8% | |
Interest coverage | x | 1.0 | 13.1 | 7.9% | |
Debt to equity ratio | x | 0.4 | 0 | 3,163.0% | |
Sales to assets ratio | x | 0.3 | 0.7 | 45.1% | |
Return on assets | % | 3.4 | 9.9 | 34.7% | |
Return on equity | % | 0.1 | 17.0 | 0.7% | |
Return on capital | % | 7.7 | 23.8 | 32.2% | |
Exports to sales | % | 22.9 | 49.6 | 46.1% | |
Imports to sales | % | 14.3 | 18.8 | 76.1% | |
Exports (fob) | Rs m | 964 | 97,091 | 1.0% | |
Imports (cif) | Rs m | 602 | 36,741 | 1.6% | |
Fx inflow | Rs m | 964 | 97,316 | 1.0% | |
Fx outflow | Rs m | 607 | 40,589 | 1.5% | |
Net fx | Rs m | 357 | 56,727 | 0.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 16,220 | 8.3% | |
From Investments | Rs m | -2,256 | -28,768 | 7.8% | |
From Financial Activity | Rs m | -1,200 | 19,191 | -6.3% | |
Net Cashflow | Rs m | -2,111 | 6,656 | -31.7% |
Indian Promoters | % | 4.5 | 54.1 | 8.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 8.0 | - | |
FIIs | % | 1.4 | 27.7 | 4.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 10.2 | 922.5% | |
Shareholders | 20,807 | 69,601 | 29.9% | ||
Pledged promoter(s) holding | % | 0.0 | 8.6 | - |
Compare DR. DATSONS LABS With: JUBILANT LIFE SCIENCES PANACEA BIOTECH WOCKHARDT GSK PHARMA FRESENIUS KABI ONCO.
Compare DR. DATSONS LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More